Effects of Caffeine on Myocardial Blood Flow:A Systematic Review by van Dijk, Randy et al.
  
 University of Groningen
Effects of Caffeine on Myocardial Blood Flow





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van Dijk, R., Ties, D., Kuijpers, D., van der Harst, P., & Oudkerk, M. (2018). Effects of Caffeine on
Myocardial Blood Flow: A Systematic Review. Nutrients, 10(8), [1083]. https://doi.org/10.3390/nu10081083
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Effects of Caffeine on Myocardial Blood Flow:
A Systematic Review
Randy van Dijk 1,2, Daan Ties 1,2 ID , Dirkjan Kuijpers 1,3 ID , Pim van der Harst 1,2 ID
and Matthijs Oudkerk 1,*
1 Center for Medical Imaging, University Medical Center Groningen, University of Groningen,
9713 GZ Groningen, The Netherlands; r.van.dijk02@umcg.nl (R.v.D.); d.ties@umcg.nl (D.T.);
t.kuijpers@haaglandenmc.nl (D.K.); p.van.der.harst@umcg.nl (P.v.d.H.)
2 Department of Cardiology, University Medical Center Groningen, University of Groningen,
9713 GZ Groningen, The Netherlands
3 HMC-Bronovo, Haaglanden Medisch Centrum, Department of Radiology,
Haaglanden Medisch Centrum-Bronovo, 2597 AX The Hague, The Netherlands
* Correspondence: m.oudkerk@umcg.nl
Received: 6 July 2018; Accepted: 10 August 2018; Published: 13 August 2018


Abstract: Background. Caffeine is one of the most widely consumed stimulants worldwide.
It is a well-recognized antagonist of adenosine and a potential cause of false-negative functional
measurements during vasodilator myocardial perfusion. The aim of this systematic review is to
summarize the evidence regarding the effects of caffeine intake on functional measurements of
myocardial perfusion in patients with suspected coronary artery disease. Pubmed, Web of Science,
and Embase were searched using a predefined electronic search strategy. Participants—healthy subjects
or patients with known or suspected CAD. Comparisons—recent caffeine intake versus no caffeine
intake. Outcomes—measurements of functional myocardial perfusion. Study design—observational.
Fourteen studies were deemed eligible for this systematic review. There was a wide range of
variability in study design with varying imaging modalities, vasodilator agents, serum concentrations
of caffeine, and primary outcome measurements. The available data indicate a significant influence of
recent caffeine intake on cardiac perfusion measurements during adenosine and dipyridamole
induced hyperemia. These effects have the potential to affect the clinical decision making by
re-classification to different risk-categories.
Keywords: caffeine; myocardial perfusion; coronary artery disease; adenosine; regadenoson; dipyridamole
1. Introduction
Noninvasive and invasive functional measurements are increasingly used to assess myocardial
perfusion in both research and the clinical setting. To unmask relevant myocardial perfusion defects,
it is essential to achieve maximal hyperemia during these measurements. The most widely used
vasodilator agents used to achieve this hyperemic effect are adenosine, regadenoson, and dipyridamole.
The hyperemic effect is primarily caused by binding to the adenosine A2A-receptor on arteriolar
vascular smooth muscle cells [1].
1.1. Vasodilator Agent Mechanisms of Action
Both adenosine and regadenoson act by directly binding to adenosine receptors. Adenosine is
a nonselective adenosine receptor agonist and binds to all the different adenosine subtypes, including
the adenosine A2B-receptor subtype [2]. Binding to this receptor causes bronchospasm in patients
with hypersensitive airways. Therefore, adenosine cannot be used in patients with either asthma or
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chronic obstructive pulmonary disease (COPD) [2–4]. Regadenoson can safely be used in patients
with hypersensitive airways, due to its selective binding to the A2A-receptor [5–8]. Dipyridamole
acts as an adenosine re-uptake inhibitor. The inhibited uptake of adenosine by cells increases the
extra-cellular adenosine concentration, increasing the amount of adenosine that is available for binding
to adenosine receptors.
1.2. Caffeine Antagonism
When adenosine binds to the G-protein coupled A2a-receptor, located on cardiac vascular
smooth muscle cells, intra-cellular production of cAMP and activation of protein kinase increase,
resulting in hyperpolarisation and consequently relaxation of vascular smooth muscle cells. Caffeine
is a well-recognized antagonist of adenosine [9]. The competitive antagonistic nature of caffeine for
the A2A-receptor is a potential cause of achieving insufficient hyperemia, resulting in false-negative
functional perfusion measurements [10]. Caffeine limits the binding of adenosine to the receptor
and consequently possibly limits cardiac vasodilation and stress adequacy. Regadenoson is a potent
selective A2A-receptor agonist that is possibly less influenced by caffeine due to the stronger affinity
for the receptor. Figure 1 is a simplified graphical illustration of the effect of the vasodilator agents and
caffeine on the A2a-receptor.
The effects of caffeine on different vasodilator myocardial perfusion measurements remains
unclear, and conflicting results have been published. By conducting a review of current literature,
two recent debate articles have attempted to shed light on the possible influence of caffeine on
myocardial perfusion imaging and its clinical impact [11,12]. However, these papers both fail to
provide a complete, unbiased systematic overview of current available evidence on the effects of
caffeine on vasodilator myocardial perfusion measurements.
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Food Safety Authority (EFSA) recently published a scientific opinion paper regarding the safety of
caffeine [14]. The papers conducted extensive surveys in 22 European countries. They report a wide
variability of mean daily caffeine intake per country. The daily intake ranged from 21.8–416.8 mg per
day in individuals ≥18 years old, with coffee being the predominant caffeine containing beverage
consumed [14]. An average cup of coffee contains approximately 85 mg of caffeine [14]. When taking
the average amount of caffeine per cup, the reported coffee intake in the ESFA database roughly
translates to a mean coffee intake of 0.25–5 cups. However, it should be recognized that the caffeine
dose varies extensively depending on several factors, for example the type of coffee bean and brewing
method [15].
1.4. Clinical Practice
In clinical practice, patients are generally instructed to refrain from consumption of caffeine
containing substances for a period ranging from 12–24 h prior to myocardial perfusion testing.
However, the adherence rate of patients to this advice is unclear and serum concentrations of caffeine
are not routinely measured in the period preceding the functional measurement. In a study by Banko
et al., 36/190 (19%) of patients who screened negative for recent caffeine ingestion by interview still
had detectable serum caffeine levels prior to the examination [16]. It is also debatable whether 12 or
24 h caffeine abstinence prior to MPI should be recommended. Carlsson et al., compared coronary
flow reserve (CFR) on MRI measured 12 and 24 h after study-induced caffeine ingestion, and showed
a significantly lower coronary flow reserve after 12 h caffeine abstinence compared to 24 h caffeine
abstinence [17].
1.5. Aim of the Study
This systematic review will summarize the evidence regarding the effects of caffeine intake
on functional measurements of myocardial perfusion in patients with suspected coronary artery
disease (CAD).
2. Methods and Results
2.1. Protocol and Registration
This systematic review was performed in concordance with the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) statement and was registered at PROSPERO under
registration number CRD42018092187.
2.2. Eligibility Criteria
Participants—healthy subjects or patients with known or suspected CAD. Comparisons—recent
caffeine intake versus no caffeine intake. Outcomes—measurements of functional myocardial perfusion.
Study design—observational.
2.3. Search Strategy
Pubmed, Web of Science, and Embase were searched using a specific electronic search strategy.
The following search strategy was used in Pubmed: (“Coffee”[Mesh] OR “Caffeine”[Mesh] OR caffeine
[tiab] OR coffee [tiab] OR coffea [tiab]) AND (“Heart” [Mesh] OR “Myocardial Ischemia” [Mesh]
OR Myocardi* [tiab] OR Cardiac [tiab] OR cardiovas* [tiab] OR heart [tiab] OR coronar* [tiab]) AND
(perfusion* [tiab] OR “Perfusion Imaging” [Mesh] OR “Magnetic Resonance Imaging” [Mesh] OR
Magnetic Resonance [tiab] OR Magnetic-resonance [tiab] OR MR [tiab] OR CMR [tiab] OR MRI
[tiab] OR “Tomography, X-ray Computed” [Mesh] OR Computed tomograph* [tiab] OR CT [tiab]
OR “Positron-Emission Tomography” [Mesh] OR Positron Emission Tomograp* [tiab] OR PET [tiab]
OR “Single Photon Emission Computed Tomography Computed Tomography” [Mesh] OR photon
Emission Computed Tomograph* [tiab] OR SPECT [tiab] OR “Fractional Flow Reserve, Myocardial”
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[Mesh] OR “Coronary Angiography” [Mesh] OR Fractional Flow Reserve [tiab] OR FFR [tiab] OR
coronary angiograph* [tiab] OR coronary-angiograph* [tiab]). The search strategy for Web of Science
and Embase was adjusted according to requirements and preferences of the different databases.
2.4. Study Selection and Data Collection
The results from the systematic search of the different databases were collected in Mendeley.
Duplicates were removed by using the automatic “check for duplicates” function within Mendeley
and an additional manual check for duplicates. Two reviewers independently screened the articles for
eligibility using the title and abstract. After title and abstract screening, the results from the reviewers
were compared and consensus was achieved in case of discrepancies. The remaining articles were read
in full text independently by both reviewers and screened for inclusion. Results of full text screening
were compared and discussed afterwards. The data extraction of eligible articles was performed with
the use of a predefined template.
2.5. Search Results
In total, 702 articles were identified. After duplicate removal, 512 articles remained. After title–abstract
screening, 38 articles were identified for eligibility for full text screening. Final number of studies
included in the systematic review after full text screening n = 14.
2.6. Study Characteristics
An overview of the patient characteristics and study design details is shown in Tables 1 and 2
respectively. The imaging modality of choice for myocardial perfusion assessment was SPECT (n = 5),
PET (n = 2), MRI (n = 3), or ICA (n = 4). The vasodilator agent used was dipyridamole (n = 3), adenosine
triphosphate (ATP) (n = 2), adenosine (n = 9), or regadenoson (n = 3).
2.7. Study Quality
Study quality was assessed with a method based on the Quality Assessment of Diagnostic
Accuracy Studies (QUADAS) forms. For the purpose of this systematic review on the effects of
caffeine on myocardial perfusion measurements, the following study design components were assessed
and graded as either low, high, or unclear risk of bias or applicability concern: 1. Patient selection
(low: Prospective patients without inappropriate exclusion, high: (Pre-)selection based on imaging
results or measurements, unclear: Not specified); 2. Intervention (low: Serum caffeine level was
>4 mg/L, high: Serum caffeine levels <4 mg/L, unclear: Not specified); 3. Analysis (low: Analysis
was interpreted without knowledge of the intervention, high: Analysis was interpreted without
adequate blinding of the intervention status, unclear: Not specified); 4. Time interval between
caffeine intervention and analysis (low: >30 min between caffeine intervention and analysis, high:
<30 min between caffeine intervention and analysis, unclear: Not specified). The results of the
study quality assessment are shown in Table 3. All studies included in this systematic review are
at high risk of selection-bias either due to pre-selection of the study population based on imaging
results (presence/absence of ischemia, presence of significant stenosis) or due to inclusion of only
healthy volunteers.
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Table 1. Patient characteristics of the studies included in the systematic review. Variables either presented as n, mean ± SD or n (%). CAD: coronary artery disease;
N: number of patients; BMI: Body mass index; MPI: Myocardial perfusion imaging. * Intervention/control: Number of patients with caffeine intervention/number of
patients without caffeine intervention.
N Intervention/Controls * Study Population Age Male BMI
SPECT
Smits 1991 8 8/0 Ischemia on baseline MPI 60 ± 7 3(38) 28 ± 4
Zoghbi 2006 30 30/0 Ischemia on baseline MPI 64 ± 9 22(73) NS
Reyes 2008 30 12/0 Ischemia on baseline MPI 66 ± 6 NS 29 ± 4
18/0 Ischemia on baseline MPI 64 ± 7 NS 27 ± 3
Lee 2012 30 30/0 Ischemia on baseline MPI 70 ± 8 21(70) NS
Tejani 2014 207 0/66 70/0 71/0 Ischemia on baseline MPI 68 ± 10.0/65.7 ± 11/69.4 ± 8.2 55(83.3)/58(82.9/51(71.8) NS
PET
Böttcher 1995 12 12/0 healthy volunteers 27 ± 6 7(58) NS
Kubo 2004 10 10/0 healthy volunteers 31 ± 6 10(100) NS
10 10/0 healthy volunteers 31 ± 6 10(100) NS
MRI
Carlsson 2015 16 16/0 healthy volunteers 41 ± 3 8(50) NS
Greulich 2017 30 30/0 Ischemia on baseline MPI 68 ± 8 25(83) NS
van Dijk 2017 98 15/50 suspected of CAD 65 ± 11 46(49) NS
9/24 suspected of CAD 65 ± 11 46(49) NS
ICA
Matsumoto 2014 42 28/14 Intermediate stenosis 70 ± 8/69 ± 10 21(75)/11(79) 24 ± 3/23 ± 4
42 28/14 Intermediate stenosis 70 ± 8/69 ± 10 21(75)/11(79) 24 ± 3/23 ± 4
42 28/14 Intermediate stenosis 70 ± 8/69 ± 10 21(75)/11(79) 24 ± 3/23 ± 4
Mutha 2014 10 10/0 Intermediate stenosis 60 ± 9 8(80) NS
Aqel 2004 10 10/0 patients with CAD 53 ± 8 10(100) NS
Nakayama 2018 30 15/15 patients with significant CAD 69 ± 10 25(83) 24 ± 3
30 15/15 patients with significant CAD 69 ± 10 25(83) 24 ± 3
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Table 2. Study design details concerning vasodilator agent, caffeine, and main findings. * Timing of caffeine intervention prior to the examination. Continuous
variables either reported as mean ± standard deviation or median (interquartile range).
Vasodilator Dosage Caffeine Dosage SerumConcentration Timing * Main Finding p-Value
SPECT
Smits 1991 Dipyridamole 0.56 mg/kg 4 mg/kg i.v. 9.7 ± 1.3 mg/L 30 min Redistribution score caffeine2.0 ± 1.1 vs. 9.0 ± 0.9 baseline <0.05
Zoghbi 2006 Adenosine 140 µg/kg/min 8 oz cup of coffee 3.1 ± 1.6 mg/L 1 h SDS caffeine 3.9 ± 2.3 vs.3.8 ± 1.9 without caffeine 0.8
Reyes 2008 Adenosine 140 µg/kg/min 2 shots espresso 6.2 ± 2.6 1 h SDS caffeine 4.1 ± 2.1 vs.baseline 12.0 ± 4.4 <0.001
Adenosine 210 µg/kg/min 2 shots espresso 5.7 ± 2.0 1 h SDS caffeine 7.8 ± 4.2 vs.baseline 7.7 ± 4.0 0.7
Lee 2012 Adenosine 140 µg/kg/min one cup of coffee 3.4 mg/Lrange 0.7–10.4 1 h
mean difference stress percent
defect −1.6 0.3
Tejani 2014 Regadenoson 400 µg




mean difference number of
ischemic segments after 200 mg
−0.61 ± 1.097, 400 mg −0.62 ±
1.367, placebo −0.12 ± 0.981
<0.001
PET
Böttcher 1995 Dipyridamole 560 µg/kg 1–2 cups of coffee range 0–8 mg/L 1–4 h Flow reserve caffeine 2.3 ± 0.7vs. 3.4 ± 0.8 <0.001
Kubo 2004 Dipyridamole 560 µg/kg 2–3 cups of coffee 3.3 ± 1.3 mg/L 1.5 h MFR caffeine 2.25 ± 0.94 vs.baseline 4.11 ± 1.44 <0.005
ATP 160 µg/kg/min 2–3 cups of coffee 3.1 ± 1.6 mg/L 1.5 h MFR caffeine 2.44 ± 0.88 vs.baseline 5.15 ± 1.64 <0.005
MRI
Carlsson 2015 Adenosine 140 µg/kg/min minimal 6 ginstant coffee NS 12 vs. 24 h
CsFR 12 h 4.31 ± 0.57 vs. 24 h
5.32 ± 0.76 0.03
Greulich 2017 Adenosine 140 µg/kg/min 200 mg orally 4.6 ± 2.2 mg/L 1 h Ischemic burden 6.9 ± 3.5caffeine vs. 7.9 ± 3.5 baseline <.001
van Dijk 2017 Adenosine 140 µg/kg/min 1–2 cups of coffee NS <4 h T1 reactivity caffeine −7.8 ± 5.0vs. control 4.3 ± 2.8 <0.001
Regadenoson 400 µg 1–2 cups of coffee NS <4 h T1 reactivity caffeine 4.4 ± 3.2vs. control 5.4 ± 2.4 0.4
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Table 2. Cont.
Vasodilator Dosage Caffeine Dosage SerumConcentration Timing * Main Finding p-Value
ICA
Matsumoto 2014 Adenosine 140 µg/kg/min 20 patients 100 or200 mg orally 2.9[1.8–4.6] mg/L NS
FFR caffeine 0.81 ± 0.09 vs.
0.78 ± 0.09 papaverine <0.001
Adenosine 170 µg/kg/min 20 patients 100 or200 mg orally 2.9[1.8–4.6] mg/L NS
FFR caffeine 0.81 ± 0.09 vs.
0.78 ± 0.09 papaverine <0.01
Adenosine 210 µg/kg/min 20 patients 100 or200 mg orally 2.9[1.8–4.6] mg/L NS
FFR caffeine 0.79 ± 0.09 vs.
0.78 ± 0.09 papaverine 0.01
Mutha 2014 Adenosine 140 µg/kg/min 4 mg/kg i.v. 16.4 ± 5.5 mg/L 7 min FFR caffeine 0.82 ± 0.11 vs.0.79 ± 0.07 baseline 0.15
Aqel 2004 Adenosine 30–50 µg bolus i.c. 4 mg/kg i.v. 3.8 ± 1.3 mg/L 5 min FFR caffeine 0.75 ± 0.14 vs.0.76 ± 0.13 0.7
Nakayama 2018 ATP 140 µg/kg/min 222 mg orally 7.3 ± 2.0 mg/L 2 min FFR caffeine 0.78 ± 0.12 vs.FFR papaverine 0.75 ± 0.14 0.002
ATP 170 µg/kg/min 222 mg orally 7.3 ± 2.0 mg/L 2 h FFR caffeine 0.77 ± 0.12 vs.FFR papaverine 0.75 ± 0.14 0.007
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Table 3. Study quality assessment. Red: High, Low: Green, Orange: Unclear risk of either bias (patient selection bias, analysis bias) or applicability concerns
(intervention and timing interval possibly not reflection of clinical practice).
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3. Discussion
The competitive nature of caffeine for the adenosine receptor poses a threat to the validity of all
myocardial perfusion modalities, irrespective of the vasodilator being used. In the past three decades,
several publications have attempted to assess the impact of (recent) caffeine ingestion on the perfusion
examinations. This systematic review aims to provide an overview of the available data and discusses
the impact of caffeine ingestion on the different perfusion modalities and vasodilator agents.
Currently, the fractional flow reserve (FFR), as measured during invasive coronary angiography
(ICA), is regarded as the reference standard for the functional assessment of myocardial perfusion.
The guidelines state that FFR measurements should be performed in case of uncertainty regarding
the significance of a coronary stenosis and that FFR measurements should be performed in case of
intermediate stenosis (40–70%) [18]. Other imaging modalities that have the potential to provide
functional information on myocardial pefusion are SPECT, PET, CT, and MRI. A recent meta-analysis
focusing on the diagnostic accuracy of these cardiac perfusion imaging modalities showed a superior
diagnostic accuracy of PET, MRI, and CT as compared to SPECT perfusion imaging [19]. SPECT
imaging suffers from a limited spatial resolution and as a result, subtle differences in myocardial
perfusion are more likely to be missed.
3.1. SPECT
Three out of five SPECT studies included in this systematic review reported a non-significant
effect of recent caffeine ingestion on the functional perfusion measurement [20–22]. The studies by Lee
et al. and Zoghbi et al. selected patients with ischemia on baseline SPECT and performed a second
SPECT after caffeine ingestion [20,21]. They reported no significant effect of caffeine ingestion on MPI.
However, both report a relatively low serum concentration of caffeine prior to performing the second
MPI, possibly underestimating the effect of caffeine. The study by Reyes et al. selected patients with
ischemia on baseline SPECT and performed a second SPECT after caffeine intervention (200 mg orally)
with either the standard dosage of 140 µg/kg/min (n = 12) or increased dosage of 210 µg/kg/min
(n = 18) [22]. The reported serum concentration of caffeine in this study was higher in both groups
when compared to Lee et al. and Zoghbi et al. A significant effect of caffeine on the functional
perfusion measurement in the group with standard adenosine dosage, but no significant effect in
the group with the increased adenosine dosage, was detected, suggesting that the effect of caffeine
can be overcome by an increased dosage of the vasodilator agent. Smits et al., report a significantly
lower redistribution score as measured on dipyridamole-SPECT after intravenous injection of caffeine
compared to baseline SPECT [23]. The serum caffeine concentration in this study was relatively high,
potentially securing a maximal effect of the caffeine intervention. The placebo-controlled study by
Tejani et al. with large sample size showed a significant decrease in the number of ischemic segments
by caffeine measured during regadenoson-SPECT as compared to placebo [24]. When considering the
study quality assessment, the two studies reporting no significant effects of the caffeine intervention
on the perfusion measurement score worse as compared to the studies reporting significant effects,
primarily driven by a lower serum concentration of caffeine.
3.2. PET
The two PET studies that report on the effects of caffeine on the functional perfusion measurements
show a significant reduction in the myocardial flow reserve and myocardial blood flow, all at relatively
low serum concentrations of caffeine during either dipyridamole or ATP induced hyperemia [25,26].
However, it should be noted that both studies included healthy individuals, making translation to
clinical practice difficult.
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3.3. MRI
All three studies that report on the effects of caffeine on adenosine MRI indicate a significant
effect on the perfusion measurements [17,27,28]. Greulich et al., showed that caffeine one hour before
the perfusion measurement at a serum level of 4.6 ± 2.2 mg/L caused a significant decrease in the
ischemic burden [27]. In the other two studies, serum caffeine concentration is not reported. However,
both studies report a significant effect on the Coronary Sinus Flow Reserve (CsFR) and T1-reactivitity,
respectively [17,28]. In the study by our research group, the T1-reactivity appeared unaffected by
recent caffeine intake in patients that underwent regadenoson perfusion MRI [28].
3.4. ICA
The four studies assessing the effects of recent caffeine intake on the FFR used either ATP or
adenosine as the vasodilator agent. The study by Nakayama et al., showed a significantly higher mean
FFR value after caffeine ingestion at a “low” (140 µg/kg/min) and “high” (170 µg/kg/min) dose of
ATP [29]. Matsumoto et al., also indicate a significant effect of recent caffeine ingestion on the FFR
measurement at adenosine dosages of 140 µg/kg/min, 170 µg/kg/min, and 210 µg/kg/min [30].
Mutha et al. and Aqel et al. both report a non-significant effect of intravenous administration of
caffeine 5–10 min before the FFR measurement [31,32]. Interestingly, the mean FFR values in the study
by Mutha et al. do suggest a significant effect [31]. The lack of significance in this study might be
due to the small study population, as they only included ten patients. The study does report that
in 2 out of the 10 patients, the FFR value changed from significant (≤0.8) to non-significant (>0.8)
after caffeine administration [31]. The study by Aqel et al., shows no significant effect of intravenous
caffeine administration at a low serum concentration of caffeine and also in a small study population of
only ten patients [32]. Additionally, the time interval between the coffee intervention and the perfusion
measurement in the studies by Mutha et al. and Aqel et al. was only several minutes, which is possibly
insufficient time for the caffeine to cause a maximal effect. The short time interval between caffeine
intervention and the perfusion measurement is also not a good representation of clinical practice.
3.5. Contributing Factors
When summarizing the presented data on the potential effects of recent caffeine ingestion on
functional perfusion measurements, several study design details appear to have an effect on the
outcome. First of all, the different vasodilator agents appear to have a different sensitivity for recent
caffeine ingestion, which also seems to be dose dependent. Almost all of the PET, MRI, and ICA
studies reporting on the effects of caffeine on adenosine perfusion imaging at the standard dosage of
140 µg/kg/min show a significant effect on the perfusion parameter [17,25–28,30,31]. Only two ICA
studies report non-significant effects [29,30]. As discussed in the previous section, possible explanations
for the lack of a significant effect in these studies are the small study population, the timing of caffeine
intervention, and the low serum concentrations of caffeine, which does not reflect the clinical setting.
Additionally, the SPECT studies with a reasonable time interval between caffeine intervention and
the perfusion measurement also indicate a significant effect on the perfusion measurement [23,24].
The SPECT and PET studies reporting on dipyridamole perfusion imaging show a significant effect of
recent caffeine ingestion [23,25,26]. The effects of recent caffeine ingestion on regadenoson perfusion
imaging remain unclear. Only two papers included in this systematic review report on the possible
effects of caffeine on regadenoson, and these papers show contradictory results without a clear
indication for the difference [24,28]. Regadenoson is increasingly used as the vasodilator agent of
choice for perfusion measurement, and further research should be conducted to better understand the
influence of caffeine intake on regadenoson perfusion.
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3.6. Clinical Relevance
For translation to clinical practice, it is essential to investigate if the effects of caffeine on the
perfusion measurements change clinical decision making. Current guidelines of the European Society
of Cardiology (ESC) indicate an area of ischemia ≥10% as high risk and a class IB indication for
revascularization for both improvement of prognosis and persisting symptoms under Optical Medical
Therapy (OMT) [33]. For MRI, this roughly translates to ≥2 segments with new perfusion defects.
The SDS score is used in SPECT analysis, with a score of >8 indicating “severe ischemia” [34].
During ICA, a cut-off value of ≤0.80 is used to indicate stenosis with guideline based indication
of revascularization [33].
Only a few articles included in this review provide information that can be used to make
a statement on the possible clinical relevance. The MRI study by Greulich et al. reports that no
conversion of a positive to a negative stress study occurred on a per patient basis, although the mean
ischemic burden was significantly reduced by one segment after caffeine administration [27]. However,
it must be noted that the study population consisted of a relatively diseased population with a high
baseline mean number of ischemic segments (7.9 ± 3.5), meaning that in this specific population,
re-classification as a result of caffeine ingestion would only occur if the detected ischemic burden
would be reduced with ≥6 segments by caffeine. Especially at the lower ranges of ischemic burden,
the reduction of a small amount of segments by caffeine ingestion might result in re-classification.
The SPECT study by Reyes et al. shows a re-classification of the SDS of patients from severe to
mild-moderate at the standard adenosine dosage of 140 µg/kg/min [22]. With strict adherence to the
guidelines, this would mean that these patients would not be referred for further treatment based on
their ischemia burden. Both Zoghbi et al. and Lee et al. report the presence of non-significant ischemia
at baseline without a change of classification after caffeine administration [20,21]. These results are
to be expected, as the general hypothesis is that caffeine administration might potentially lower the
amount of detected ischemia and not increase it, making “re-classification” in these studies impossible.
The ICA study by Matsumoto et al. indicates a possible clinical relevant effect of caffeine on FFR
measurements [30]. As stated previously, the current cut-off value of FFR for indicating relevant
myocardial ischemia is≤0.80. The mean FFR value at baseline in their study population with adenosine
dosage of either 140 µg/kg/min, 170 µg/kg/min, or 210 µg/kg/min indicates significant disease
with an FFR ≤0.8 (FFR 0.78 ± 0.09 papaverine). After caffeine ingestion, the mean FFR values in the
140 µg/kg/min and 170 µg/kg/min groups change from significant to non-significant >0.8 (FFR after
caffeine administration 0.81± 0.09), clearly indicating the potential of recent caffeine ingestion to cause
re-classification during ICA.
3.7. Stress Adequacy
The T1-reactivity can be used as an imaging biomarker for the assessment of stress adequacy
during vasodilator perfusion MRI. It is useful to measure stress adequacy either before the perfusion
acquisition or retrospectively during image post-processing and evaluation [35]. We believe that
reporting the T1-reactivity will aid in the proper interpretation of MRI perfusion images and that the
imaging biomarker should be used as a quality check for stress adequacy.
4. Conclusions
When considering the studies with high study quality, the available data indicate a significant
influence of recent caffeine intake on cardiac perfusion measurements during adenosine and
dipyridamole induced hyperemia in SPECT, PET, MRI, and ICA. Recent caffeine ingestion prior
to functional perfusion measurements has the potential to affect clinical decision making by
re-classification to different risk-categories.
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Implications of Key Findings
Caffeine intake prior to perfusion measurements should be discouraged and in case of recent
caffeine intake, rescheduling of the procedure or switching to regadenoson as the vasodilator agent
of choice should be considered. During vasodilator perfusion MRI, the T1-reactivity can be used as
a biomarker to assess stress adequacy and to indicate patients at risk of false-negative perfusion results.
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